RU2711932C2 - Нейтрализующие антитела к вирусу гриппа B и пути их применения - Google Patents

Нейтрализующие антитела к вирусу гриппа B и пути их применения Download PDF

Info

Publication number
RU2711932C2
RU2711932C2 RU2017104638A RU2017104638A RU2711932C2 RU 2711932 C2 RU2711932 C2 RU 2711932C2 RU 2017104638 A RU2017104638 A RU 2017104638A RU 2017104638 A RU2017104638 A RU 2017104638A RU 2711932 C2 RU2711932 C2 RU 2711932C2
Authority
RU
Russia
Prior art keywords
antibody
influenza
virus
seq
antibodies
Prior art date
Application number
RU2017104638A
Other languages
English (en)
Russian (ru)
Other versions
RU2017104638A (ru
RU2017104638A3 (enExample
Inventor
Давиде КОРТИ
Антонио Ланцавеккья
Николь КАЛЛЕВААРД-ЛЕЛАЙ
Цин ЧЖУ
Эбони БЕНДЖАМИН
Лесли УОЧТЕР
Энди ЮАНЬ
Джозефин Мэри МАКОЛИФФ
Original Assignee
МЕДИММЬЮН, ЭлЭлСи
Хумабс Биомед Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕДИММЬЮН, ЭлЭлСи, Хумабс Биомед Са filed Critical МЕДИММЬЮН, ЭлЭлСи
Publication of RU2017104638A publication Critical patent/RU2017104638A/ru
Publication of RU2017104638A3 publication Critical patent/RU2017104638A3/ru
Application granted granted Critical
Publication of RU2711932C2 publication Critical patent/RU2711932C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2017104638A 2014-07-15 2015-07-14 Нейтрализующие антитела к вирусу гриппа B и пути их применения RU2711932C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024804P 2014-07-15 2014-07-15
US62/024,804 2014-07-15
PCT/US2015/040385 WO2016011035A2 (en) 2014-07-15 2015-07-14 Neutralizing anti-influenza b antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020100073A Division RU2739952C2 (ru) 2014-07-15 2015-07-14 Нейтрализующие антитела к вирусу гриппа b и пути их применения

Publications (3)

Publication Number Publication Date
RU2017104638A RU2017104638A (ru) 2018-08-15
RU2017104638A3 RU2017104638A3 (enExample) 2019-07-17
RU2711932C2 true RU2711932C2 (ru) 2020-01-23

Family

ID=55079157

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017104638A RU2711932C2 (ru) 2014-07-15 2015-07-14 Нейтрализующие антитела к вирусу гриппа B и пути их применения
RU2020100073A RU2739952C2 (ru) 2014-07-15 2015-07-14 Нейтрализующие антитела к вирусу гриппа b и пути их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020100073A RU2739952C2 (ru) 2014-07-15 2015-07-14 Нейтрализующие антитела к вирусу гриппа b и пути их применения

Country Status (10)

Country Link
US (6) US10294292B2 (enExample)
EP (1) EP3169407A4 (enExample)
JP (4) JP6837434B2 (enExample)
CN (4) CN113563462B (enExample)
AU (3) AU2015289805B2 (enExample)
BR (1) BR112017000640A2 (enExample)
CA (1) CA2954780A1 (enExample)
MX (3) MX392761B (enExample)
RU (2) RU2711932C2 (enExample)
WO (1) WO2016011035A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3052192T3 (pl) 2013-10-02 2021-04-06 Medimmune, Llc Przeciwciała neutralizujące przeciwko grypie A i ich zastosowania
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
LT3303384T (lt) 2015-06-01 2021-10-11 Medimmune, Llc Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
JP7611908B2 (ja) * 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用
US20250320279A1 (en) * 2021-11-30 2025-10-16 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
CN118420751B (zh) * 2022-07-09 2025-04-08 东莞市朋志生物科技有限公司 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167382A1 (en) * 1999-03-31 2002-01-02 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EP2919813B1 (en) * 2012-11-13 2018-10-24 F.Hoffmann-La Roche Ag Anti-hemagglutinin antibodies and methods of use

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6093156A (en) 1996-12-06 2000-07-25 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US8101553B1 (en) 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
EP2119793A1 (en) 2000-06-28 2009-11-18 Glycofi, Inc. Methods for producing modified glycoproteins
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
CA2490423A1 (en) 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
AU2003251809A1 (en) 2002-07-11 2004-02-02 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
RU2366662C2 (ru) 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
RU2390351C2 (ru) 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
AU2007205935B2 (en) 2006-01-17 2013-07-11 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
AU2007226856A1 (en) 2006-03-21 2007-09-27 Michael Rynkiewicz Methods for humanizing antibodies and humanized antibodies made thereby
US7615220B2 (en) 2006-04-07 2009-11-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-18 receptor
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
EP2769992B1 (en) 2006-10-02 2020-12-30 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008066691A2 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
JP5346820B2 (ja) 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
AU2009275227A1 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
JP5882058B2 (ja) 2008-11-07 2016-03-09 ファブラス エルエルシー 組合せ抗体ライブラリー及びその使用
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
AU2011344126B2 (en) 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
US8961978B2 (en) * 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
LT3418300T (lt) 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
WO2013070565A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
BR112014013640A8 (pt) 2011-12-05 2021-03-16 Trellis Bioscience Llc anticorpos úteis em imunização passiva para influenza
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
PL3052192T3 (pl) 2013-10-02 2021-04-06 Medimmune, Llc Przeciwciała neutralizujące przeciwko grypie A i ich zastosowania
CN113563462B (zh) * 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
LT3303384T (lt) 2015-06-01 2021-10-11 Medimmune, Llc Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
US20170240617A1 (en) 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167382A1 (en) * 1999-03-31 2002-01-02 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EP2919813B1 (en) * 2012-11-13 2018-10-24 F.Hoffmann-La Roche Ag Anti-hemagglutinin antibodies and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Игнатьева А. В. "Особенности антигенной структуры гемагглютинина, распознаваемые антителами против современных вирусов гриппа А подтипов Н5 и Н1". Авто на соискание ученой степени кандидата биологических наук, Москва, 2012. *
Игнатьева А. В. "Особенности антигенной структуры гемагглютинина, распознаваемые антителами против современных вирусов гриппа А подтипов Н5 и Н1". Автореферат на соискание ученой степени кандидата биологических наук, Москва, 2012. *

Also Published As

Publication number Publication date
CA2954780A1 (en) 2016-01-21
US20250263470A1 (en) 2025-08-21
WO2016011035A3 (en) 2016-03-10
US20240076357A1 (en) 2024-03-07
RU2020100073A3 (enExample) 2020-06-10
CN106573154B (zh) 2021-06-15
RU2017104638A (ru) 2018-08-15
US11174304B2 (en) 2021-11-16
US20220025020A1 (en) 2022-01-27
CN113563462B (zh) 2024-08-13
CN113173990B (zh) 2024-10-29
MX2022006558A (es) 2022-07-11
RU2017104638A3 (enExample) 2019-07-17
CN119161468A (zh) 2024-12-20
MX2022006561A (es) 2022-07-11
JP2017523805A (ja) 2017-08-24
AU2015289805A1 (en) 2017-03-02
CN113563462A (zh) 2021-10-29
JP7209754B2 (ja) 2023-01-20
WO2016011035A8 (en) 2016-12-08
US12325740B2 (en) 2025-06-10
US20200190169A1 (en) 2020-06-18
CN113173990A (zh) 2021-07-27
AU2020233635B2 (en) 2024-01-18
CN106573154A (zh) 2017-04-19
MX392761B (es) 2025-03-21
JP2023052268A (ja) 2023-04-11
AU2015289805B2 (en) 2020-06-25
MX2017000595A (es) 2017-10-12
EP3169407A4 (en) 2018-04-25
WO2016011035A2 (en) 2016-01-21
RU2739952C2 (ru) 2020-12-30
US11787853B2 (en) 2023-10-17
JP7453430B2 (ja) 2024-03-19
US20190233504A1 (en) 2019-08-01
US10294292B2 (en) 2019-05-21
JP2024069341A (ja) 2024-05-21
US20170218054A1 (en) 2017-08-03
AU2024202231A1 (en) 2024-05-02
BR112017000640A2 (pt) 2017-11-14
RU2020100073A (ru) 2020-03-03
JP2021074013A (ja) 2021-05-20
JP6837434B2 (ja) 2021-03-03
EP3169407A2 (en) 2017-05-24
US10519221B2 (en) 2019-12-31
AU2020233635A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US12492240B2 (en) Neutralizing anti-influenza A antibodies and uses thereof
US12325740B2 (en) Neutralizing anti-influenza B antibodies and uses thereof
RU2784915C2 (ru) Нейтрализующие антитела к вирусу гриппа b и пути их применения
HK40061870A (en) Neutralizing anti-influenza b antibodies and uses thereof
HK40057425A (en) Neutralizing anti-influenza b antibodies and uses thereof
HK40061870B (zh) 中和抗乙型流感抗体及其用途
HK40057425B (zh) 中和抗乙型流感抗体及其用途